Robert Layne Kruse,Karl-Dimiter Bissig,Stephen M. G. Gottschalk,Thomas C. T. Shum
申请号：
US16334712
公开号：
US20190307798A1
申请日:
2017.09.29
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised.
